je.st
news
Tag: interim
Ruric Ab Board of Directors approves release of the Interim Report for January - September 2013
2013-11-30 06:18:51| Appliances - Topix.net
Press Release November 29, 2013 RURIC AB Board of Directors approves release of the Interim Report for January - September 2013 On 29 November 2013 Board of Directors of Russian Real Estate Investment Company AB approved Interim Report for January - September 2013.
Tags: report
september
january
board
Auriant Mining (publ) publishes interim report for the period from January - September 2013
2013-11-28 15:02:47| Appliances - Topix.net
Highlights: Consolidated revenue from gold and gold equivalents for 9 months 2013 increased by 95% to MSEK 230.3 compared to 9 months 2012 in amount of MSEK 118.1 .
Tags: report
september
january
period
Raysearch Laboratories AB (PUBL) Interim Report January 1 - September 30, 2013
2013-11-28 05:33:57| Appliances - Topix.net
JANUARY 1 - SEPTEMBER 30, 2013 Net sales for the period amounted to SEK 114.4 M A loss after tax of SEK 25.9 M was reported, as well as a loss per share of SEK 0.76 The operating loss was SEK 26.1 M Cash flow amounted to a negative SEK 28.0 M First orders for RayStation from Spain and France Collaboration agreement signed with IBA Partnership ... (more)
Tags: report
september
january
interim
True North Energy Names Steedley Interim CEO
2013-11-21 16:25:00| OGI
He will remain interim CEO until the right CEO is identified.
Additional Interim Data for Mercks Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma
2013-11-18 18:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma that showed an estimated overall survival rate of 81 percent at one year across all MK-3475 monotherapy doses evaluated. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] next »